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n INTRODUcTION
Intravenous drug use is a well-recognized risk factor for infectious spondylodiscitis, especial-
ly in HIV-infected patients [1, 2]. Back pain is the 
most common initial symptom, and fever is not 
invariably present. The differential diagnosis in-
cludes disc herniation, vertebral compression 
fracture, inflammatory spondyloarthropathies, 
degenerative or metastatic spinal diseases [3]. 
The latter can be associated with various can-
cers including hepatocellular carcinoma (HCC), 
a complication of hepatitis C virus (HCV)/HIV 
coinfection [6]. Moreover the introduction of 
highly active antiretroviral therapy (ART) has 
led to a decrease in AIDS related mortality and 
AIDS defining cancers including Kaposi’s sarco-
ma, non-Hodgkin lymphoma and invasive cervi-
cal cancer. In contrast, the rates of various cancers 
including HCC have failed to decrease with ART, 
and to date represents the majority of cancers in 
HIV patient population [4, 5].
n cASE REPORT
Here, we describe the case of a caucasian 51-year-
old male with a history of intravenous drug use 
who was admitted to our hospital in July 2012 for 
back pain at the dorsal spine segment. His past 
medical history revealed seroconversion to HIV-1 
in 1994, and to HCV in 1999. The patient enjoyed 
relatively good health although he continued to 
use intravenous illicit drugs even on replacement 
therapy with methadone. In 2007, laboratory data 
were the followings (Table 1): CD4+ 960 cells/µl, 
CD4+ cell percentage 33%, HIV RNA 17 000 cop-
ies/ml, HCV RNA 1.46 x 10^4 UI/ml. At that 
time, he had started the antiretroviral therapy 
(ART) regimen including tenofovir, lamivudine 
and unboosted fosamprenavir. Since the patient 
was diagnosed a severe anxious depressive syn-
drome, treatment of chronic hepatitis C had been 
excluded. In 2009, he underwent splenectomy for 
an abdominal trauma. 
At hospital admission, in July 2012, the body 
temperature was 37°C and physical examination 
was unremarkable, except for hepatomegaly. No 
neurological deficit was found. The blood exam-
inations showed the following abnormalities: se-
rum C-reactive protein 61 mg/L (normal value <5 
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mg/L), white blood cells 25.2 x 10^3/µL, neutro-
phils 17.2x10^3/µL. In addition, CD4+ cell count 
was 1866/µL, CD4+ cell percentage 36%, HIV 
RNA undetectable (<50 copies/mL), and HCV 
RNA 1.28x10^5 UI/mL (Table 1). MRI of the spine 
showed gadolinium enhancement of T8-T9 ver-
tebrae, discs and surrounding paravertebral soft 
tissues (Figure 1). An open biopsy of the spinal 
lesion was performed and the histological exami-
nation showed osteonecrosis with neutrophil and 
eosinophil infiltrate; the culture of biopsy sample 
turned out to be positive for Pseudomonas aerugi-
nosa, sensitive to all anti-pseudomonas antibiot-
ics. These results were consistent with the diag-
nosis of infectious spondylodiscitis. The patient 
was treated with targeted intravenous therapy 
initially with ceftazidime and ciprofloxacin for 
3 weeks, then for the following 3 weeks ceftazi-
dime was changed with amikacin once a day to 
continue the treatment as an outpatient, while 
oral ciprofloxacin was continued for a total of 5 
months, with improvement of spinal symptoms 
and imaging abnormalities and normalization 
of C reactive protein. In March 2013, the patient 
referred worsening of the dorsal pain and right 
costal pain, then he performed a FDG-PET scan 
which showed an abnormal radionuclide concen-
tration in T8-T9 facet joints, but no involvement 
of the disc and paravertebral soft tissues. This 
was consistent with the healing of spondylodis-
Table 1 - Biochemical and virological data of the patient.
2007
HAART start
July 2012
Diagnosis of spondylodiscitis
March 2013
End of antibiotic therapy
July 2013
Diagnosis of HCC
CD4 (cells/µL) 960 1866 2100 2560
CD4 (%) 33 36 35 35
HIV-RNA (copies/mL) 17000 Undetectable Undetectable
HCV-RNA (UI/mL) 1,46x104 1,28x105
PCR (mg/mL) 61 <5 <5
WBC (cells/µL) 25000 11000 13070
Figure 1 - MRI of the thoracic spine (fat sat T2 weighted 
image) in July 2012: changes consistent with spondylo-
discitis at T8-T9 level. No other significant findings.
Figure 2 - MRI of the thoracic spine (contrasted fat sat 
T1 weighted images) in July 2013. Secondary deposits 
involving the vertebral body of T3-T6, T10-T12 and L1. 
The T3-T6 lesions largely involve adjacent soft tissues, 
as well. The fusion of T8-T9 is due to the previous 
spondylodiscitis.
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citis. No abnormal radionuclide concentration 
was found in other anatomic sites. In May 2013, 
the patient was receiving his ART regimen and 
methadone. Laboratory data showed CD4+ cell 
count 2587/µL, CD4+ cell percentage 35%, HIV 
RNA undetectable, and serum alpha fetoprotein 
within the normal range, as well. The liver ultra-
sound didn’t show focal lesions. Then the patient 
continued to complain of worsening back pain. 
In July 2013, the MRI of the spine revealed sev-
eral gadolinium-enhancing vertebral lesions in 
the T3-T6, T10-T12, and L1 segments (Figure 2). 
In addition, the chest CT scan showed multiple 
contrast-enhanced costal arch lesions near the 
vertebral alterations described above. One of such 
lesions was targeted for a percutaneous TC-guid-
ed biopsy whose histology revealed poorly dif-
ferentiated cancer cells. The immunohistochemi-
cal reaction for cytoplasmic TTF-1 was diffusely 
positive, an immunophenotypic profile typical of 
HCC. In fact, the TC scan of the abdomen showed 
a contrast-enhanced lesion (8 cm in diameter) at 
the VIII segment of liver, with surrounding multi-
ple smaller satellite nodular lesions. Even though 
treated with sorafenib, the patient died after 8 
months from the HCC diagnosis.
n DIScUSSION
The introduction of HAART has led to a decrease 
in the incidence of AIDS-defining cancers (Ka-
posi’s Sarcoma, Non-Hodgkin’s lymphoma and 
invasive cervical cancer). On the other hand, an 
increase in the incidence of non AIDS-defining 
cancers, including carcinoma of the anus, testis, 
lung, colon, Hodgkin disease and hepatocellular 
carcinoma (HCC) has been reported [4, 5].
Focusing on HCC, a prospective study performed 
by the French Mortavic group on a cohort of 25178 
HIV positive patients revealed that deaths due to 
HCC rose 5-fold (4,7% to 25%) from 1995 to 2001 
and that nearly all patients who died from HCC 
had an HCV co-infection [7].
These data have been confirmed by Giordano et 
al. who conducted a retrospective cohort study 
on 11678 HIV-only and 4761 HCV-HIV coinfected 
patients reporting that coinfected patients had an 
hazard ratio for cirrhosis of 9.24 compared with 
HIV-only, and an hazard ratio for HCC of 5.35 
compared with HIV-only patients [8]. 
On the other hand, Di Benedetto et al. reported 
that in the HAART era HIV co-infection is not 
associated with a higher incidence of HCC in 
hepatitis C cirrhotic patients. In fact in their pro-
spective cohort study conducted in hepatitis C 
cirrhotic patients with and without HIV co-in-
fection between 1999 and 2010 they revealed that 
the incidence of HCC in HIV-HCV co-infected 
patients and HCV mono-infected patients was 
1.54 (95% confidence interval = 0.5 to 3.6) and 3.03 
(95% confidence interval = 1.22 to 6.23) cases per 
100 person-year respectively [9]. 
These results have not been confirmed by Kramer 
et al. who recently published a restrospective co-
hort study on U.S. veterans where the risk of HCC 
in HCV- and HIV-coinfection was higher than 
HCV monoinfection; in fact in this study the over-
all age-adjusted incidence rate of HCC in monoin-
fected patients was 2.99/1000 person-years vs. 
4.44/1000 person-years in coinfected patients. In 
the latter ones, presence of cirrhosis and a recent 
low CD4 cell count <200 were associated with an 
increased risk for HCC [10] .
Moreover HCC seems to have a more rapid evo-
lution in HIV-HCV coinfected patients than in 
HCV monoinfection. In fact in a multivariate 
analysis performed in 2004 by the Italian cooper-
ative group on AIDS and Tumours (GICAT) in 41 
cases of HCC in HIV positive individuals (from 
a joint Italian and Spanish database) compared 
with 384 HIV-negative controls, the HIV patients 
with HCC were much younger at presentation 
(age 40-46 vs 60-70) and had more advanced infil-
trating disease; in this study they observed also a 
trend to more advanced cirrhosis at presentation 
in the HIV positive population [11].
Also in our patient the HCV-associated HCC re-
sulted to be very rapidly evolving despite effec-
tive ART regimen; in fact in the present case the 
neoplastic lesions were identified by neither the 
FDG-PET scan nor the liver ultrasound performed 
almost 4 and 2 months before the diagnosis of the 
metastatic lesions, respectively. In our opinion 
there is no link between the previous spondylo-
discitis and the development of HCC metastasis, 
as different vertebral sites were involved.
Treatment of chronic hepatitis C for patients with 
HIV infection is essential to prevent the transition 
to liver cirrhosis, the development of HCC and 
liver failure. Interferon plus ribavirine therapy re-
duces liver related complications and mortality in 
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patients with sustained virological response [12]. 
Anyway the poor tolerability of Peg-IFN + RBV 
double therapy and of triple therapy with Peg-
IFN + RBV + boceprevir or telaprevir has been a 
serious obstacle to treating chronic hepatitis pa-
tients with HIV/HCV coinfection. New interfer-
on-free antiviral therapies for chronic hepatitis C 
in HIV infected patients are under investigation. 
Sulkowski et al. found rates of sustained virolog-
ical response of 76% in patients with HCV-geno-
type 1, 88% in those with genotype 2 and 67% in 
those with genotype 3 coinfected with HIV who 
received the oral, interferon-free combination of 
sofosbuvir and ribavirin [13]. In the phase II COS-
MOS trial, where patients were treated with SMV 
+ SOF with or without RBV, SVR was achieved 
in 92% previous non-responders with METAVIR 
scores F0-F2 and 94% previous non-respond-
ers and treatment-naive patients with METAVIR 
scores F3-F4 [14]. Among interferon-free therapeu-
tic regimens for treatment of genotype 1 chronic 
hepatitis C in HIV coinfection under investiga-
tions are also the combination daclatasvir + sim-
eprevir +/- ribavirin in the LEAGUE-1 trial and 
paritaprevir/r, ombitasvir, dasabuvir and RBV in 
the Turquoise-I trial. Preliminary data of both tri-
als have shown good rates of sustained virological 
response [15, 16].
In conclusion this clinical case report shows how 
hepatocarcinoma might have a fast progression 
to a metastatic disease in a patient with chronic 
hepatitis C and HIV infection. The hope is that in 
the next future all these new interferon free regi-
mens will change the clinical outcome of chron-
ic hepatitis C-HIV coinfected patients, thanks to 
their high rates of sustained virological response 
in patients with cirrhosis, as well. 
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Back pain and spine tenderness over the involved spine 
segment are common clinical findings of a number of 
relative benign conditions. However, back pain may 
be the presenting symptom of vertebral metastases in 
patients with systemic cancer, including hepatocellular 
carcinoma, a not uncommon complication in HCV-HIV 
infected patients. We describe a case of a 51-year-old 
intravenous drug user with HIV and HCV co-infection 
who developed dorsal spondylodiscitis due to Pseu-
domonas aeruginosa, which improved following antibiot-
SUmmARY
ic therapy. Three months after the end of therapy, the pa-
tient referred recurrence of back pain. The MRI showed 
different vertebral lesions of the dorsal spine and costal 
arch which turned out to be hepatocellular carcinoma 
metastasis at the histological examination. The patient 
had never been treated with the interferon-ribavirine 
combination therapy because of a major depressive syn-
drome. Interferon-free regimens are urgently required 
for HIV-HCV coinfected patients, especially when inter-
feron-based regimens are contraindicated.
La rachialgia può essere il sintomo di varie patologie relati-
vamente benigne, ma si può presentare anche come sintomo 
d’esordio di metastasi vertebrali da varie neoplasie primitive, 
incluso l’epatocarcinoma, una complicanza non infrequente 
nei pazienti con confezione HIV-HCV.
Di seguito riportiamo il caso clinico di un paziente di 51 
anni, tossicodipendente, con coinfezione da HIV e HCV che 
ha sviluppato una spondilodiscite da Pseudomonas aeru-
ginosa, trattata con successo con terapia antibiotica mirata. 
Dopo tre mesi dal termine della terapia antibiotica il pa-
ziente aveva presentato una recrudescenza della rachialgia. 
La RMN eseguita in tale occasione rivelava numerose lesio-
RIASSUNTO
ni vertebrali e costali, che all’esame istologico risultavano 
metastasi di epatocarcinoma. Il paziente non era mai stato 
trattato in precedenza per epatite cronica da HCV, in quanto 
affetto da depressione maggiore, che controindicava il trat-
tamento con PEG-IFN. Questo caso suggerisce quanto sia 
importante l’introduzione di regimi antivirali per l’epatite 
cronica da HCV senza interferone, in particolar modo per 
quei pazienti in cui quest’ultimo farmaco sia controindicato 
per la presenza di comorbidità. Inoltre, questo caso sottolinea 
l’importanza della biopsia e dell’esame istologico nella dia-
gnosi differenziale delle lesioni vertebrali, in particolar modo 
nei pazienti con infezione da HIV.
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